---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-355635"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2026-08-18T20:51:26+00:00"
generated_at: "2026-08-18T20:52:09.953348+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iridex Q2 revenue down 7% to $12.6M; glaucoma G6 up 19%, retina weak

## Summary
- Total revenue $12.6M, down 7% YoY; net loss $1.3M ($0.07/share) vs $1.0M loss prior year.
- Cyclo G6 family revenue $3.9M (+19% YoY) on 17,700 probes sold (+35% volume); retina revenue $6.5M vs $8.0M.
- Non-GAAP adjusted EBITDA loss $0.4M vs +$21K prior year; operating cash flow positive in Q2.
- Reaffirms FY2026 revenue guidance $51-53M; adjusted opex $19-19.5M; cash $4.7M.
- Retina decline due to Middle East disruptions and China sell-through; expects improvement with Pascal platform.

## SEC filing metadata
- accession: 0001193125-26-355635
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2026-08-18T20:51:26+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/0001193125-26-355635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/irix-20260818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-355635
- JSON: https://secwatch.observer/filing/0001193125-26-355635.json
- Plain text: https://secwatch.observer/filing/0001193125-26-355635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.